Cell Source (Cell Source) Total Assets : $0.25 Mil (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cell Source Total Assets?

Cell Source's Total Assets for the quarter that ended in Sep. 2023 was $0.25 Mil.

During the past 12 months, Cell Source's average Total Assets Growth Rate was -16.90% per year. During the past 3 years, the average Total Assets Growth Rate was 29.10% per year. During the past 5 years, the average Total Assets Growth Rate was 19.60% per year.

During the past 11 years, Cell Source's highest 3-Year average Total Assets Growth Rate was 67.50%. The lowest was -39.10%. And the median was 15.70%.

Total Assets is connected with ROA %. Cell Source's annualized ROA % for the quarter that ended in Sep. 2023 was -1,754.75%. Total Assets is also linked to Revenue through Asset Turnover. Cell Source's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

Cell Source Total Assets Historical Data

The historical data trend for Cell Source's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Total Assets Chart

Cell Source Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

0.07

0.12

0.45

0.31

0.41

Cell Source Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Assets	Get a 7-Day Free Trial															0.36	0.41	0.23	0.36	0.25

Cell Source Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cell Source's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	-12.634	+	13.044
	=	0.41

Cell Source's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	-16.03	+	16.279
	=	0.25

Cell Source (OTCPK:CLCS) Total Assets Explanation

Total Assets is connected with ROA %.

Cell Source's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-5.352	/	( (0.362	+	0.248)	/ 2 )
	=	-5.352	/	0.305
	=	-1,754.75 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cell Source's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0	/	( (0.362	+	0.248)	/ 2 )
=	0	/	0.305
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cell Source Total Assets Related Terms

Thank you for viewing the detailed overview of Cell Source's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell Source (Cell Source) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website

https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.

Executives

George Verstraete	director	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave	director, 10 percent owner	341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner	10 percent owner
Yoram Drucker	director	31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown	director	100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat	director, officer: CEO and CFO	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty	director	C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman	director, 10 percent owner	C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines

From GuruFocus

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Board

By PRNewswire PRNewswire • 02-25-2021